Evidence map›Paper›PMID 36351697›Full record

ArticleLupus science & medicine2022

Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study.

Miao Shao, Miao Miao, Xia Zhang, Xiaoying Zhang, Yuan An, Huifang Guo, Lingyan Lei, Qing Zhao, Yanjie Ding, Jin Lin and 40 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus science & medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors at 20 institutions in 1 country.

Miao ShaoDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.ORCID 0000-0002-7979-8136
Miao MiaoDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Xia ZhangDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Xiaoying ZhangDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Yuan AnDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Huifang GuoDepartment of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Lingyan LeiDepartment of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Qing ZhaoDepartment of Rheumatology and Immunology, Huaihe Hospital of Henan University, Kaifeng, Henan, China.
Yanjie DingDepartment of Rheumatology and Immunology, Huaihe Hospital of Henan University, Kaifeng, Henan, China.
Jin LinDepartment of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Rui WuDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Feng YuRenal Division, Department of Medicine, Peking University First Hospital, Beijing, China.ORCID 0000-0003-3060-6233
Yucui LiDepartment of Rheumatology and Immunology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, Shanxi, China.
Huali MiaoDepartment of Rheumatology and Immunology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, Shanxi, China.
Liyun ZhangDepartment of Rheumatology and Immunology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, Shanxi, China.
Yan DuDepartment of Rheumatology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Ruiying JiaoDepartment of Rheumatology and Immunology, Hulunbuir People's Hospital, Hulunbuir, Inner Mongolia, China.
Lixia PangDepartment of Rheumatology and Immunology, Hulunbuir People's Hospital, Hulunbuir, Inner Mongolia, China.
Li LongDepartment of Rheumatology and Immunology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Xueming YaoDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China.
Xiaofei ShiDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China.
Fei WangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China.
Luping CuiDepartment of Rheumatology, Shanxi Provincial People's Hospital, Taiyuan, Shanxi, China.
Lei ZhangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Shengyun LiuDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Fuai LuDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, China.
Kangkai LuoDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, China.
Simeng ZhaoDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, China.
Yongfu WangDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, China.
Xiao WuDepartment of Rheumatology and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Qingwen WangDepartment of Rheumatology and Immunology, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China.
Hongjiang LiuDepartment of Rheumatology and Immunology, The First People's Hospital of Yichang, Yichang, Hubei, China.
Shulin SongDepartment of Rheumatology and Immunology, The First People's Hospital of Yichang, Yichang, Hubei, China.
Xiaoyuan ZhouDepartment of Nephrology and Rheumatology, Zunyi Medical University Hospital, Zunyi, Guizhou, China.
Xiaoping ZhangDepartment of Nephrology and Rheumatology, The PLA 960 Hospital, Jinan, Shandong, China.
Shumei ShiDepartment of Nephrology and Rheumatology, The PLA 960 Hospital, Jinan, Shandong, China.
Hong ZhuDepartment of Rheumatology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Yao ChenDepartment of Hematology and Rheumatology, Wu zhong People's Hospital, Wuzhong, Ningxia, China.
Honglian YuDepartment of Rheumatology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
Jie WuDepartment of Rheumatology and Immunology, Xinxiang Central Hospital, Xinxiang, Henan, China.
Ruiyun YuDepartment of Rheumatology and Immunology, Xinxiang Central Hospital, Xinxiang, Henan, China.
Wenqiang FanDepartment of Rheumatology and Immunology, Xinxiang Central Hospital, Xinxiang, Henan, China.
Shuang LiuDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Jian XuDepartment of Rheumatology and Immunology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Zhibin ChenDepartment of Nephrology, The Affiliated Yueqing Hospital of Wenzhou Medical University, Yueqing, Zhejiang, China.
Lianjie ShiDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Jing HeDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Xuewu ZhangDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China.
Zhanguo LiDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China doctorliru123@163.com li99@bjmu.edu.cn.ORCID 0000-0002-2590-6242
Ru LiDepartment of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China doctorliru123@163.com li99@bjmu.edu.cn.
Peking University · CNShanxi Medical University · CNInner Mongolia University of Science and Technology · CNKunming Medical University · CNXinxiang Central Hospital · CNFirst Affiliated Hospital of Henan University of Science and Technology · CNFirst Affiliated Hospital of Zhengzhou University · CNHebei Medical University · CNHenan University Huaihe Hospital and Huaihe Clinical Institute · CNHulunbuir University · CNNingxia Medical University · CNPeking University Shenzhen Hospital · CNShanxi Academy of Medical Sciences · CNYichang Central People's Hospital · CNFirst Affiliated Hospital Zhejiang University · CNGuizhou University · CNNanchang University · CNPeople's Liberation Army 401 Hospital · CNSecond Affiliated Hospital of Zhejiang University · CNUniversity of Electronic Science and Technology of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveInfection is a major cause of death in patients with SLE. This study aimed to explore the infection rate in patients with SLE receiving a low dose of intravenous cyclophosphamide (IV-CYC).

methodsClinical parameters of 1022 patients with SLE from 24 hospitals in China were collected. Patients were divided into the short-interval and lower-dose (SILD, 400 mg every 2 weeks) IV-CYC group and the high-dose (HD, 500 mg/m

resultsCompared with HD IV-CYC, the infection rate of the SILD IV-CYC group was significantly lower (13.04% vs 22.27%, p=0.001). Respiratory tract infection (10.28% vs 15.23%, p=0.046) and skin/soft tissue infection (1.78% vs 4.3%, p=0.040) were significantly decreased in the SILD IV-CYC group. Moreover, infections occurred most likely in patients with SLE with leucopenia (OR 2.266, 95% CI 1.322 to 3.887, p=0.003), pulmonary arterial hypertension (OR 2.756, 95% CI 1.249 to 6.080, p=0.012) and >15 mg/day of glucocorticoid (OR 2.220, 95% CI 1.097 to 4.489, p=0.027).

conclusionsSILD IV-CYC showed a lower frequency of infection events than high-dose IV-CYC in patients with SLE.

Indexed as

Immunosuppressive AgentsLupus Erythematosus, SystemicCyclophosphamideGlucocorticoidsHumansCyclophosphamideGlucocorticoidsImmunosuppressive AgentscyclophosphamideSLEtherapeutics

Identifiers

PMID36351697
PMCPMC9644361
OpenAlexW4308650976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.